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ABSTRACT
Background: Locally advanced pancreatic cancer (LAPC) is associated with high 
mortality, and biomarker-driven treatment approach is currently lacking. This study 
evaluated safety and efficacy of a combination approach of chemotherapy followed 
by chemo-radiotherapy (CRT) +/- cetuximab, and the prognostic role of miR-21 in 
patients with LAPC treated with a multimodality approach. 
Patients and Methods: This was a randomised phase II trial in which patients 
with inoperable LAPC were offered gemcitabine and capecitabine (GEM-CAP) for 16 
weeks. Patients with stable disease or response after GEM-CAP were randomised to 
capecitabine or UFT plus radiotherapy (RT) (A), or capecitabine or UFT plus cetuximab 
plus RT (B). The primary outcome of the study was overall survival (OS). Clinical 
outcome was compared according to baseline circulating miR-21 levels. 
Results: 17 patients were enrolled and treated with GEM-CAP, with 13 patients 
achieving disease control and being randomised to arms A (n:7) and B (n:6). After a 
median follow-up of 61.2 months, median progression free survival (PFS) was 10.4 
months and 12.7 months, median OS was 15.8 months and 22.0 months in arms A 
and B respectively (p > 0.05). Patients with high baseline plasma miR-21 had worse 
PFS (3.5 vs. 12.7 months; p:0.032) and OS (5.1 vs 15.3 months; p:0.5) compared 
to patients with low miR-21. Circulating miR-21 levels reflected miR-21 expression 
within the tissues.
Conclusions: Addition of Cetuximab to CRT following induction chemotherapy did 
not improve survival. High miR-21 baseline plasma expression was associated with 
poor clinical outcome in LAPC patients treated with induction chemotherapy followed 
by chemo-radiotherapy.
INTRODUCTION
Despite the recent advancements in diagnosis and 
management of solid malignancies, pancreatic ductal 
adenocarcinoma (PDAC) remains a highly lethal disease 
[1]. Majority of patients present with locally advanced 
unresectable (40-50%) or metastatic disease (40%) [2]. 
Management of Locally advanced Pancreatic Cancer 
(LAPC) remains largely under-researched with lack of 
evidence both in terms of optimal treatment approach 
and biomarkers that could inform such an approach 
[3]. Although previously conducted studies failed to 
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demonstrate any definite survival advantage of chemo-
radiotherapy (CRT) over chemotherapy (CT) alone 
[4, 5], retrospective analysis of 4 phase II-III studies 
demonstrated that patients without disease progression 
after 3 months of CT, followed by CRT had a longer 
survival than those continuing on CT alone [6]. A 
pooled meta-analysis of SAKK and UK studies showed 
clinical activity for gemcitabine and capecitabine (GEM-
CAP) combination [7, 8], suggesting this could be 
considered a useful neo-adjuvant chemotherapy (NACT) 
approach. Recent evidence suggests that addition of 
epidermal growth factor receptor (EGFR) inhibition to 
CRT is feasible and promising in terms of efficacy [9]. 
Furthermore, EGFR is known to be upregulated in up 
to 69-95% of advanced pancreatic cancers [10, 11] and 
the EGFR tyrosine kinase inhibitor erlotinib combined 
with gemcitabine demonstrated survival benefit over 
gemcitabine alone [12]. Cetuximab, an anti-EGFR 
antibody has been safely combined with chemotherapy 
and radiotherapy in patients with LAPC and with other 
cancers [13-15]. Additionally, pre-clinical studies have 
demonstrated improved efficacy when gemcitabine 
was combined with radiotherapy in PDAC, suggesting 
independent radio-sensitive effects of cetuximab in this 
cancer [16, 17].
MicoRNAs (miRNAs) are non-coding RNAs that 
have been implicated in post-transcriptional regulation of 
gene expression. Growing evidence suggests the role of 
miRNAs in regulation of carcinogenesis and modulation 
of drug response [18, 19]. Over-expression of miR-21 
is known to be associated with decreased sensitivity to 
gemcitabine in vitro and with poor clinical outcomes 
in retrospective clinical studies [20-23]. Furthermore, 
miRNAs can be detected both in tissue and plasma 
thus suggesting their role as potentially useful clinical 
biomarkers [24].
In this randomised phase II trial of patients with 
LAPC, we sought to evaluate an optimal radiosensitivity 
agent in patients who achieved disease control (DC) after 
neo-adjuvant GEM-CAP. The PERU trial was closed 
prematurely in June 2013 because the emergent data from 
LAP-07 study [25] failed to demonstrate any meaningful 
survival advantage with the use of CRT approach 
following first-line chemotherapy in LAPC. However, we 
have taken advantage of this cohort of patients by carrying 
out a preliminary study on the role of circulating miRNAs 
as prognostic biomarkers in LAPC. Despite growing 
evidence supporting the value of circulating miRNAs 
in predicting clinical outcome in cancer patients, most 
of the data is generated in retrospective and unselected 
populations, and data in prospective clinical trials are 
lacking. Here we report miR-21 plasma expression and 
its association with clinical outcomes in this prospective 
study of LAPC patients treated with a combination 
approach.
RESULTS
Baseline characteristics
Seventeen patients, all with de novo LAPC were 
enrolled and treated with NACT. Patients and tumour 
characteristics have been summarised in Table 1. Sixteen 
(93%) patients received at least 3 cycles of NACT. Median 
relative dose intensity of gemcitabine was 76.2%, while 
that of capecitabine was 89.6%. Eighty-three percent of 
patients received the planned dose of RT (Supplementary 
Table 1).
Figure 1: PFS according to randomisation. All randomised patients (n = 13) who achieved disease control with neoadjuvant 
chemotherapy were randomised to arms A (n = 7) and B (n = 6). After a median follow-up of 61.2 months, no differences in median PFS 
from randomization were observed between arm A [median 7.6 months (95%CI: 5.1 - 10.3)] and arm B [median 9.5 months (95%CI: 4.1 - 
15.0)]. RT = radiotherapy, FLUO: Fluoropyrimidine and CETUX = cetuximab.
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Efficacy and safety
Thirteen patients who achieved disease control 
rate (DCR) with NACT (PR = 11.8%, SD = 64.7%) were 
randomised to arms A (n = 7) and B (n = 6). Objective 
Response Rate (ORR) following CRT was 14.3% and 
33.3% in groups A and B respectively (p > 0.05). After 
a median follow-up of 61.2 months, median Overall 
Survival (OS) from time of NACT was 15.8 (95% CI: 
14.5 - 17.9) and 22.0 (95% CI: 0 - 45.5; p > 0.05) months 
while median Progression Free Survival (PFS) was found 
to be 10.4 (95% CI: 7.8 - 13.0) and 12.7 (95% CI: 7.3 
- 18.0; p > 0.05) months in the two arms respectively 
(Figure 1). 1-year survival was 100% and 66.7% (p = 
Figure 2: PFS according to miR-21 expression. Circulating miR-21 was assessed in baseline plasma and used as a binary variable 
to differentiate patients with high miR-21 and low miR-21. miR-21 expression significantly correlated with PFS.
Table 1: Clinico-pathological characteristics of all 17 registered patients receiving NACT
ALL
N                                           (%)
Age (years)
Median, (range) 61.0 (47-76)
Gender
Male
Female
11
6
64.7
35.3
ECOG Performance Status
0
1
3
14
17.7
82.3
Site of Primary 
Head of Pancreas
Body of Pancreas
13
4
76.5
23.5
Radiological T-stage
T3
T4
TX
1
13
3
5.9
76.5
17.6
Radiological N-stage
N0
N1
NX
5
9
3
29.4
52.9
17.6
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Table 2: Adverse events during chemo-radiation with or without cetuximab
TOXICITY CRT ARM A (RT+FLUO)(n = 6)
CRT ARM B (RT + FLUO + CETUX)
(n = 6)
Grade I/II
N (%)
Grade III/IV
N (%)
Grade I/II
N (%)
Grade III/IV
N (%)
Anaemia 3 (50) 5 (83.3)
Hyperglycaemia 5 (71.4) 4 (66.7)
Hyponatraemia 5 (83.3) 1 (16.7) 4 (66.7)
Dry skin 2 (33.3) 4 (66.7)
Constipation 4 (66.7)
Rash/desquamation 4 (66.7)
Thrombocytopenia 4 (66.7) 3 (50)
Lethargy 4 (66.7) 3 (50)
Hypocalcaemia 3 (50)
Hand foot syndrome (PPE) 3 (50) 2 (33.3)
Diarrhoea 5 (83.3) 2 (33.3)
Anorexia 2 (33.3) 2 (33.3)
Nausea 3 (50)
Neutropenia 2 (33.3)
Fatigue 1 (14.2) 1 (16.7) 2 (33.3)
Hypokalaemia 2 (33.3)
Vomiting 2 (28.6) 1 (16.7)
Abdominal pain 1 (16.7) 1 (16.7) 1 (16.7)
Dehydration 2 (33.3)
Non Neutropenic infection 1 (16.7) 1 (16.7)
Urinary frequency 1 (16.7)
Allergic reaction 1 (16.7)
Dizziness 1 (16.7) 1 (16.7)
Dyspepsia 2 (28.6) 1 (16.7)
Dyspnoea 1 (16.7) 1 (16.7)
Psoriasis 1 (16.7)
Acneiform rash 1 (16.7)
Hyper-pigmentation 1 (16.7)
Hypercalcaemia 1 (16.7)
Hyperkalaemia 1 (16.7)
Hypoglycaemia 1 (16.7)
Hypomagnesaemia 1 (16.7)
Nail changes 1 (16.7)
Peripheral oedema 1 (16.7)
Stomatitis 1 (16.7)
Syncope 1 (16.7)
Taste alteration 1 (16.7)
Table 3: miR-21 expression and efficacy data in all registered patients 
Number of 
events
Number of 
subjects
Median Survival 
(Months)
(95% CI)
1 Year Survival
(95% CI)
Hazard Ratio
(95% CI) p-value
(PFS)
Low miR-21
High miR-21
6
6
6
6
12.7 (6.9 – 18.4)
3.5 (2.8 – 4.3)
66.7 (29.1 – 100)
16.7 (0 – 46.5)
1.0
4.7 (1.1 – 19.7) 0.032
(OS)
Low miR-21
High miR-21
6
5
6
6
15.3 (7.3 – 23.3)
5.1 (0 – 10.7)
83.3 (53.5 – 100)
33.3 (0 – 70.9)
1.0
1.46 (0.41 – 5.21) 0.564
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0.801, 95% CI: 29.1 - 100) in arms A and B respectively. 
OS in all registered patients (n = 17) was 15.3 months 
(95% CI: 13.0 - 17.5) and 64.7% (95% CI: 42.0 - 87.4) 
of the patients were alive at 1-year. NACT approach with 
GEM-CAP and combining cetuximab with CRT or with 
chemotherapy were both found to be safe (Table 2 and 
Supplementary Table 2).
miR-21 molecular analysis results
Of the 17 registered patients, plasma samples were 
available in 16 cases. Four cases could not be analysed 
because haemolysis occurred in the samples. Circulating 
miR-21 expression was assessed by Taqman assay in 
the baseline plasma sample in 12 patients, who were 
divided in two groups (low and high miR-21) by using 
the median as a cut-off. When miR-21 expression was 
validated by digital droplet polymerase chain reaction 
(ddPCR), patients were assigned to the same groups 
(copies of miR-21/ml of plasma ranged between 1.1E+04 
and 1.4E+08). All these patients underwent NACT with 
GEM-CAP. Amongst these patients, 3 patients progressed 
on NACT, and 8 were further randomized to arm A (n = 
4) and arm B (n = 4). DCR post NACT was 100% vs. 
40% in patients with low and high miR-21 respectively 
(p = 0.06). Interestingly, all patients who progressed 
after NACT had high values of circulating miR-21 at 
Figure 3: Circulating miR-21 expression reflects expression of miR-21 in tumour tissue. Matched baseline plasma and 
Formalin-Fixed-Paraffin-Embedded tissues were analysed. Circulating miR-21 expression was quantitated by ddPCR, and tissue miR-21 
expression was assessed by ISH. Patients with high circulating levels of miR-21 had tumours with high miR-21 expression in cancer cells 
in the tissues.
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baseline (Supplementary Table 3). Patients with high 
miR-21 plasma levels had a significantly worse PFS 
from registration [3.5 (95% CI: 2.8 - 4.3) vs. 12.7 (95% 
CI: 6.9 - 18.4 months); p = 0.032], and a non-significant 
trend on OS was observed (Figure 2 & Table 3). When 
all randomised patients were analysed, patients with low 
miR-21 were found to have better DCR at 6 weeks of 
chemotherapy [100% (5/5) vs. 50% (1/2)] and better PFS 
(9.5 vs. 4.2 months). In order to investigate if circulating 
levels of miR-21 reflected expression of miR-21 in the 
primary tumour, we assessed miR-21 expression by In Situ 
Hybridization (ISH) in PDAC tissues. Matched baseline 
PDAC tissue was retrieved in 4 cases. Interestingly, miR-
21 expression was negative in tumours of patients with 
low circulating miR-21, while moderate to strong miR-21 
expression was detected in tumour cells of patients with 
high circulating miR-21 (Figure 3). 
DISCUSSION
Genetic heterogeneity is common in PDAC and 
limits the efficacy benefits gained from conventional anti-
cancer therapies [23]. A significant proportion of patients 
presents with LAPC, where treatment approach is less 
well defined. The role of radiotherapy in management of 
LAPC remains a debatable issue. Induction chemotherapy 
is often used to better identify tumours that are already 
associated with micro-metastatic disease and are unlikely 
to benefit from localised treatments. Recent data from the 
LAP-07 trial suggested that CRT following NACT may 
improve quality of life by prolonging the time without 
treatment and reducing the risk of local progression, 
despite no impact on OS. The CirCe 07 translational 
ancillary study to the LAP-07 suggested that specific 
biomarkers, such as positivity of Circulating Tumour Cells 
(CTC) at baseline, could define patients with worse OS 
[26]. However, CTC positivity was not associated with 
improvement in PFS from CRT suggesting that further 
investigations are required in this field. A retrospective 
analysis of LAPC treated by CRT or CT alone suggested 
that molecular biomarkers, such as copy number variation 
of ACTN4 can better select patients who benefit from CRT 
over CT alone [27]; however, prospective validation of 
such findings remains sparse in the literature. 
In this study we present data from a prospective 
clinical study of CRT following NACT that evaluated 
the role of miR-21, which is known to be associated with 
pancreatic carcinogenesis [22, 28]. miR-21 is known 
to be highly over-expressed in PDAC and has a known 
association with tumour aggressiveness and poor clinical 
outcome [29-31]. Plasma levels of miR-21 were found 
to be elevated in PDAC patients compared to healthy 
controls [32]. We have previously shown that miR-21 
modulates response to Fluorouracil (FU) [33]. miR-
21 was found to be an independent prognostic factor in 
unselected cohorts of PDAC patients undergoing GEM-
based palliative or FU-based adjuvant chemotherapy 
[34-35]. To our knowledge, our study is the first study to 
demonstrate the potential prognostic role of circulating 
miR-21 in a prospective cohort of patients with LAPC. 
Despite the small numbers in our series, we were able to 
show that patients with low expression of miR-21 benefit 
more from chemotherapy with GEM-CAP and have a 
prolonged PFS when radiotherapy is combined to NACT. 
Lack of association of low miR-21 with improved OS is 
likely to be related to differences in subsequent palliative 
treatments and small sample size. PDAC shows high 
cellular heterogeneity and source of circulating miR-
21 can either be represented by tumour cells or stromal 
cells. Recent evidence suggests that miR-21 within the 
cancer associated fibroblasts can predict response to 
drug treatment more than cancer cell-derived miR-21. 
In order to investigate the source of circulating miR-
21 in our series, we assessed miR-21 expression in the 
matched tissues collected at the same time of the plasma 
collection. Although numbers are too low to draw definite 
conclusions, our study is a proof of concept that free 
plasma miR-21 reflects the expression of miR-21 in the 
cancer cells and therefore can be used as a surrogate for 
tumoural miR-21. 
Our data support the notion that altered expression 
of plasma miR-21 may be a prognostic biomarker that 
may help to guide multi-modality treatment in LAPC. 
Acknowledging the limitations of our study in terms of 
small numbers, we believe that this analysis explores 
the role of the miR-21 in a prospective cohort of LAPC 
and provides further rationale for expanding biomarker-
based studies in PDAC. Based on our findings, miR-21 
appears to have prognostic role in patients with LAPC. 
Moreover, our clinical data suggest that treatment with 
more efficacious contemporary NACT regimens may 
provide enhanced systemic control prior to consideration 
of localised therapy options such as radiotherapy, and thus 
may optimise outcomes. This approach may be particularly 
relevant in patients with low miR-21 expression, where 
better outcomes can be potentially expected. Further 
studies to elucidate the mechanisms by which miR-21 may 
increase tumour sensitivity to therapies are warranted. 
PATIENTS AND METHODS
Patients
Eligible patients had histologically confirmed 
unresectable LAPC and had a World Health Organisation 
performance status (PS) of 0-2. Patients were considered 
unresectable based on at least one of the three features 
including a) extensive peri-pancreatic lymph node 
involvement, b) encasement/occlusion of the superior 
mesenteric vein (SMV) or SMV/portal vein confluence or 
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c) direct involvement of superior mesenteric artery, coeliac 
axis, inferior vena cava or aorta. Patients who received 
prior chemotherapy and those with CT scan-evidence of 
metastatic disease were not allowed. All patients were 
required to have adequate bone marrow, liver and renal 
functions as defined by the study protocol.
Study
Pancreatic Cancer Erbitux, Radiotherapy and UFT 
(PERU) (ISRCTN: 65518365) was a randomised phase 
II study of neo-adjuvant GEM-CAP for 16 weeks in 
patients with LAPC. Gemcitabine 1000mg/m2 was given 
as an intravenous (i.v.) infusion over 30 minutes and 
was administered on days 1, 8 and 15 in a 28 day cycle. 
Capecitabine 1660mg/m2 daily (in two divided doses) was 
administered orally for 21 days followed by 7 days’ rest. 
Following NACT, patients were randomised 
between: A) UFT/LV or capecitabine plus radiotherapy 
(RT) or B) UFT/LV or capecitabine plus cetuximab 
plus RT. Capecitabine 1600mg/m2/day was given 
concomitanlty with RT alone in arm A or with i.v. 
Cetuximab (400mg/m2 on day 1 and 250mg/m2 
subsequently,weekly for 5 weeks) in arm B.
The aim of this study was to assess overall survival 
(OS) of patients receiving CRT or CRT + cetuximab 
after NACT. The primary endpoint of PERU study was 
1-year OS; secondary end points included progression free 
survival (PFS), objective response rate (ORR), biomarkers 
of clinical benefit. The study had a Data Monitoring 
Committee (DMC) which monitored efficacy and safety 
on the study.
Radiotherapy quality assurance
RT (45Gy in 25 fractions) was given to tumour bed 
including involved nodes and tumour margins, followed 
by a boost to gross tumour volume (GTV) of 9Gy in 5 
fractions (5.4 Gy in 3 fractions was accepted as boost if 
normal tissue tolerance was exceeded). CT planning scan 
was performed between weeks 13 to 16 of NACT. Patients 
were treated using a 3D conformal technique; the 95% 
isodose was required to cover the planning target volume 
(PTV). GTV was defined by contrast enhanced CT and 
consisted of tumour and any enhancing lymph nodes > 
5mm in the typical pancreatic drainage basin. No elective 
nodal irradiation was performed. The boost consisted of 
macroscopic visible disease with a 5mm margin in all 
directions. 
Statistical analysis
Based on the pooled GERCOR studies, the lower 
limit of 95% confidence interval (CI) for the 1-year 
survival rate of chemotherapy alone group was estimated 
to be 35%. A 1-year OS rate from the time of registration 
of ≥55% was considered acceptable (p1) and a 1-year OS 
rate from the time of registration of < 35% was estimated 
to be ruled out as unacceptable (p0). Giving 10% drop out 
rate, a total of 45 patients per arm (90 patients in total) 
were to be randomised to reach 2-sided α = 0.05 and 
80% power. However, the trial was closed pre-maturely, 
following emergent data from LAP-07 [25] study failing 
to demonstrate survival advantage with the use of NACT 
followed by CRT. This decision was endorsed by DMC. 
Intention to Treat (ITT) population and safety 
population were defined as all patients who got randomised 
to a treatment arm as they had omplete response (CR), 
partial response (PR) or stable disease (SD) after 12 weeks 
of beginning NACT and had at least one post treatment 
visit. Patients were analysed as randomised. OS and PFS 
were calculated using Kaplan Meier in association with 
long-rank test for the two arms in the ITT population. 
1-year OS rate was displayed with 95% CIs. 
Molecular analysis
Baseline whole blood was collected in EDTA-
treated tubes; cells were removed by centrifugation for 
15 minutes at 1,500 x g using a refrigerated centrifuge 
(4°C). Supernatant was collected and centrifuged for 
further 10 minutes at 1,500 x g at 4C. The resulting 
supernatant was designated plasma and was transferred 
into clean RNAse free tubes and stored at -80. RNA was 
extracted from 200uL using the miRCURY RNA isolation 
kit (Exiqon, Denmark) following supplier instructions. 
Fixed starting volume was maintained for each sample. 
2ul of RNA was then reverse transcribed and assessed for 
miR-21 expression (Taqman, Lifetechnologies, Paisley 
UK, code 000397). In the Kaplan Meier analysis, patients 
were divided in two groups: low miR-21 and high miR-21 
according to median value. Validation by digital droplet 
PCR (Biorad, Berkeley, CA, USA) was performed as 
previously described [36]. A no template control and a 
negative control for each reverse transcription reaction 
were included in every assay and at least 10000 droplets 
were assessed for each sample. miR-21 expression was 
assessed blinded to clinical data.
miR-21 was assessed in tissue by RNA In Situ 
Hybridization (ISH). A locked nucleic acid (LNA) 
probe with complementarity to miR-21 was labeled with 
5′-digoxigenin and synthesized by Exiqon (Denmark), and 
ISH performed as previously described [37]. 
Given the lack of activity of Cetuximab we have 
pooled the two arms together and analysed OS and PFS 
by above/below median miR-21 value by Cox regression 
to obtain 95% CIs. 
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